- Home
- MIST vs IMAB Comparison
MIST vs IMAB Comparison
Compare MIST & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- IMAB
- Stock Information
- Founded
- MIST 2003
- IMAB 2014
- Country
- MIST Canada
- IMAB United States
- Employees
- MIST N/A
- IMAB N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- MIST Health Care
- IMAB Health Care
- Exchange
- MIST Nasdaq
- IMAB Nasdaq
- Market Cap
- MIST 89.8M
- IMAB 73.9M
- IPO Year
- MIST N/A
- IMAB 2020
- Fundamental
- Price
- MIST $1.71
- IMAB $2.50
- Analyst Decision
- MIST Strong Buy
- IMAB Strong Buy
- Analyst Count
- MIST 2
- IMAB 2
- Target Price
- MIST $7.50
- IMAB $5.50
- AVG Volume (30 Days)
- MIST 658.4K
- IMAB 994.9K
- Earning Date
- MIST 08-07-2025
- IMAB 05-15-2025
- Dividend Yield
- MIST N/A
- IMAB N/A
- EPS Growth
- MIST N/A
- IMAB N/A
- EPS
- MIST N/A
- IMAB N/A
- Revenue
- MIST N/A
- IMAB N/A
- Revenue This Year
- MIST N/A
- IMAB N/A
- Revenue Next Year
- MIST N/A
- IMAB N/A
- P/E Ratio
- MIST N/A
- IMAB N/A
- Revenue Growth
- MIST N/A
- IMAB N/A
- 52 Week Low
- MIST $0.63
- IMAB $0.60
- 52 Week High
- MIST $2.75
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- MIST 60.15
- IMAB 67.42
- Support Level
- MIST $1.67
- IMAB $2.29
- Resistance Level
- MIST $1.80
- IMAB $2.69
- Average True Range (ATR)
- MIST 0.08
- IMAB 0.35
- MACD
- MIST -0.01
- IMAB 0.00
- Stochastic Oscillator
- MIST 43.24
- IMAB 64.53
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).